Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.
Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Yao S, et al. Among authors: hayes df. Pharmacogenomics J. 2014 Jun;14(3):241-7. doi: 10.1038/tpj.2013.32. Epub 2013 Sep 3. Pharmacogenomics J. 2014. PMID: 23999597 Free PMC article. Clinical Trial.
Phase II evaluation of thalidomide in patients with metastatic breast cancer.
Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF. Baidas SM, et al. Among authors: hayes df. J Clin Oncol. 2000 Jul;18(14):2710-7. doi: 10.1200/JCO.2000.18.14.2710. J Clin Oncol. 2000. PMID: 10894870 Clinical Trial.
New prognostic factors for breast cancer recurrence.
Isaacs C, Stearns V, Hayes DF. Isaacs C, et al. Among authors: hayes df. Semin Oncol. 2001 Feb;28(1):53-67. doi: 10.1016/s0093-7754(01)90045-4. Semin Oncol. 2001. PMID: 11254867 Review.
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Esteva FJ, et al. Among authors: hayes df. J Clin Oncol. 2003 Mar 15;21(6):999-1006. doi: 10.1200/JCO.2003.05.068. J Clin Oncol. 2003. PMID: 12637463 Clinical Trial.
A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V, Gallagher A, Kleer CG, Singh B, Freedman M, Haddad BR, Isaacs C, Warren R, Brown M, Cullen J, Trock B, Hayes DF. Stearns V, et al. Among authors: hayes df. Clin Cancer Res. 2004 Dec 15;10(24):8332-40. doi: 10.1158/1078-0432.CCR-04-0297. Clin Cancer Res. 2004. PMID: 15623610 Clinical Trial.
A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients.
Isaacs C, Slack R, Gehan E, Ballen K, Boccia R, Areman E, Kramer R, Hayes DF, Herscowitz H, Lippman M. Isaacs C, et al. Among authors: hayes df. Breast Cancer Res Treat. 2005 Sep;93(2):125-34. doi: 10.1007/s10549-005-4445-y. Breast Cancer Res Treat. 2005. PMID: 16187232 Free article. Clinical Trial.
481 results